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of internalized pneumococci in response to pneumococcal 
infection. In a murine model of infection with  S. pneumoniae , 
using mice transgenic for human IL-37b (IL-37tg), we ob-
served an initial decrease in cytokine expression of IL-6, 
TNF-α, and IL-1β in the lungs, followed by a late-phase en-
hancement of pneumococcal burden and subsequent in-
crease of proinflammatory cytokine levels. Additionally, a 
marked increase in recruitment of alveolar macrophages 
and neutrophils was noted, while TRAIL mRNA was reduced 
3-fold in lungs of IL-37tg mice, resulting in necrotizing pneu-
monia with augmented death of infiltrating neutrophils, en-
hanced bacteremic spread, and increased mortality. In con-
clusion, we have identified that IL-37 modulates several core 
components of a successful inflammatory response to pneu-
mococcal pneumonia, which lead to increased inflamma-
tion, tissue damage, and mortality.  © 2017 S. Karger AG, Basel 
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 Abstract 
 Streptococcus pneumoniae  infections can lead to severe 
complications with excessive immune activation and tissue 
damage. Interleukin-37 (IL-37) has gained importance as a 
suppressor of innate and acquired immunity, and its effects 
have been therapeutic as they prevent tissue damage in au-
toimmune and inflammatory diseases. By using RAW macro-
phages, stably transfected with human IL-37, we showed a 
70% decrease in the cytokine levels of IL-6, TNF-α, and IL-1β, 
and a 2.2-fold reduction of the intracellular killing capacity 
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 Introduction 
 Streptococcus pneumoniae is one of the most impor-
tant human respiratory pathogens and remains the most 
common cause of pneumonia worldwide  [1] . Especially 
in individuals with medical comorbidity, pneumococcal 
disease is associated with substantial morbidity and mor-
tality  [2] . Acute pulmonary infection, caused by  S. pneu-
moniae , is characterized by high bacterial burden in the 
lung, a pronounced alveolar influx of polymorphonucle-
ar cells, and a risk of bacterial systemic spread  [3] . It is 
widely assumed that excessive immune activation and tis-
sue damage facilitate bacterial invasion, a severe compli-
cation of pneumococcal pneumonia  [4] . For that reason, 
limiting proinflammatory cytokine responses and leuko-
cyte influx at the suitable time is of vital importance for 
ensuring an appropriate resolution of inflammation. In 
murine pneumococcal pneumonia, it was shown that 
apoptotic death of alveolar macrophages (AMs), medi-
ated by TRAIL (TNF-related apoptosis-inducing ligand), 
reduces lung inflammation triggered by bacterial chal-
lenge  [5] . 
 Interleukin-37 (IL-37) belongs to the family of IL-1 
cytokines. Unlike other members of the family, IL-37 
broadly suppresses innate immunity  [6] . A growing body 
of evidence has found IL-37 to be a fundamental anti-
inflammatory cytokine, with the capacity to reduce and 
suppress immune responses in inflammatory and auto-
immune diseases, thereby preventing tissue damage  [6] . 
Reducing endogenous IL-37 in human cells revealed that 
IL-37 limits the production of cytokines induced by Toll-
like receptors (TLRs) and IL-1β secretion  [7] . Transgene 
expression of human IL-37 in mice (IL-37tg) results in 
markedly reduced inflammation in models of endotoxic 
shock, colitis, myocardial infarction, lung, and spinal 
cord injury  [6, 8–11] . In addition, it was reported that in-
tranasal administration of IL-37 prevents acute allergic 
inflammation in mice  [12] . In parallel, in a murine infec-
tion model with  Aspergillus fumigatus , treatment with re-
combinant exogenous IL-37 decreased pulmonary tissue 
damage by preventing the activation of the NLRP3 in-
flammasome and reducing IL-1β secretion  [13] . 
 Elevated levels of IL-37 have been observed in humans 
with chronic inflammatory and autoimmune diseases 
such as chronic obstructive pulmonary disease, rheuma-
toid arthritis, and inflammatory bowel disease, suggest-
ing that the induction of IL-37 expression is an appropri-
ate response to limit disease severity  [14–17] . Notably, 
most of these chronic conditions are known to be associ-
ated with a greatly amplified risk for pneumococcal infec-
tions and increased mortality  [2, 18] . In accordance, re-
cent studies demonstrated that IL-37tg mice are more 
susceptible to disseminated  Candida albicans infection 
 [19] . In human tuberculosis, IL-37 has been found to in-
hibit the production of proinflammatory cytokines and to 
decrease the phagocytic activity of macrophages  [20] . 
Hence, the anti-inflammatory and immunosuppressive 
properties of IL-37 might play an important role in dis-
ease progression and outcome of pneumococcal pneu-
monia.
 In this study, we investigated the impact of IL-37 on 
pneumococcal infection using RAW 264.7 macrophages, 
stably transfected with human IL-37 and a clinically rel-
evant IL-37 transgenic mouse model. Due to the lack of a 
homologous IL-37 murine gene, our studies were based 
on vector-controlled human IL-37 murine expression 
models where IL-37 expression is regulated by a constitu-
tive CMV promoter  [7] . The CMV promotor of pIRES is 
constitutively active, and is commonly used to drive ex-
pression in most cells. However, like other members of 
the IL-1 family, IL-37 shows no species specificity, and 
transgene expression of human IL-37 in RAW macro-
phages as well as in mice is similar to the expression in 
human cells  [21] . IL-37 expression in the inflamed tissue 
counteracts the effective control of pneumococcal growth, 
greatly augments inflammation accompanied with in-
creased influx and necrosis of neutrophils, and intensifies 
tissue damage. 
 Materials and Methods 
 Ethics Statement 
 This work was performed in accordance with the recommen-
dations of the European Guidelines for Animal Welfare of the Eu-
ropean Commission. All procedures were reviewed and accepted 
by the governmental institution Thüringer Landesamt für Ver-
braucherschutz (TLV) and are described in the applications for 
animal experiments 02-067/11 and 02-043/15. 
 Animals 
 Transgenic mice were generated using the full-length precur-
sor cDNA of  IL-37b isoform driven by the CMV promoter for con-
stitutive expression  [7] . For IL-37, 5 splice variants (IL-37a–e) 
were identified, at which the isoform IL-37b is the largest and in-
cludes 5 of 6 exons  [22] . Referring to embryo transfer, using 
C57BL/6J mice, heterozygous IL-37tg siblings were mated with 
each other to generate homozygous IL-37tg animals. IL-37-nega-
tive siblings were bred and used as wild-type mice (WT) in all ex-
periments. Both mice strains were kept under specific pathogen-
free conditions. Mice were supplied with the same rodent chow 
and water and maintained on a 12-h light-dark cycle in a tempera-
ture- and humidity-controlled environment. For all experiments, 
we used 9-week-old female mice.
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 Cells 
 Murine macrophages (RAW 264.7; ATCC) were stably trans-
fected with either the  IL-37b (RAW-IL-37) isoform in pIRES or 
pIRES-empty (RAW-vector; lacking  IL-37b ), using the FuGENE 
HD transfection reagent (PROMEGA)  [7] . The CMV promotor of 
pIRES is constitutively active, and is commonly used to drive ex-
pression in most cells. Stably transfected cells were cultured in 
Dulbecco’s Modification of Eagle’s Medium (DMEM; Gibco) sup-
plemented with 10% heat inactivated fetal calf serum (FCS; Bio-
chrom), 10,000 U/mL of penicillin, and 10,000 μg/mL of strepto-
mycin) at 37   °   C in a humidified atmosphere containing 5% CO 2 . 
Stably transfected cells were selected with Geneticin (1: 100; Gibco, 
50 mg/mL), added to the medium.
 Bacterial Strains 
 S. pneumoniae WT D39 serotype 2 (encapsulated) and the iso-
genic nonencapsulated D39 ∆ cps  was a kind gift from Hester 
Bootsma, PhD (Laboratory of Pediatric Infectious Diseases, Rad-
boud University Nijmegen Medical Center, the Netherlands). The 
capsular polysaccharide represents one of the most important 
pneumococcal virulence factors  [23] . For comparison of virulence, 
we used for the in vitro studies the encapsulated WT D39wt sero-
type 2 and the nonencapsulated mutant D39Δ cps . Based on the fact 
that a reduced amount of capsule can also convert the pneumococ-
cus into a more nonpathogenic state in terms of its ability to evade 
the immune system  [24] , we only used the encapsulated D39wt for 
our in vivo infection studies, which reduces the amount of capsule 
polysaccharide for an intimate contact with host cells in vivo  [24] . 
Both strains were grown in a first step overnight on 5% sheep blood 
agar plates (BD) at 37   °   C/5% CO 2 . Cultures were then inoculated 
into Todd-Hewitt Yeast (THY) medium and grown to mid-log 
phase (optical density at 600 nm [OD 600 ] of 0.285) at 37   °   C/5% 
CO 2 . Pneumococci were harvested by centrifugation at 4,500 rpm 
for 5 min and 4  °  C, and resuspended in sterile PBS. 
 Murine Infections 
 IL-37tg and WT mice were anaesthetized by intraperitoneal 
injection of medetomidine (0.5 mg/kg), midazolam (5 mg/kg), and 
fentanyl (0.05 mg/kg). Mice were then infected intranasally with a 
single dose of 20 μL of bacterial suspension ( S. pneumoniae  D39
5 × 10 7 CFU per mice) or an adequate volume of PBS (uninfected). 
We determined the optimal infection dose, leading to a LD 90 , by 
comparing 5 × 10 6 , 5 × 10 7 , and 5 × 10 8 CFU per inoculation and 
mouse. For every experiment, the inoculum was plated on blood 
agar plates and CFU were counted after 20 h of culture at 37  °  C and 
5% CO 2 for control of the infection dose. Clinical conditions, rec-
tal temperature (BAT-12 Microprobe Thermometer; Physitemp 
Instruments, Clifton, NJ, USA), and body weight were monitored 
twice a day.
 Bronchoalveolar Lavage Fluid and Determination of 
Bronchoalveolar Lavage Fluid Leukocyte Subsets 
 Leukocyte subsets in bronchoalveolar lavage fluid (BALF) were 
determined from whole-lung washes of uninfected and  S. pneu-
moniae -infected mice. Animals were anesthetized by intraperito-
neal injection of ketamine (160 mg/kg) and xylazine (75 mg/kg), 
and sacrificed by bleeding via the vena cava. Afterwards, tracheas 
were rinsed through a 24-gauge needle with 800-μL aliquots of 
cold PBS, supplemented with 10% FCS (Biochrom) and 2 m M 
EDTA (SERVA) 3 times, followed by careful aspiration. BALF was 
collected in sterile tubes on ice and centrifuged at 500  g at 4  °  C for 
10 min. For differential cell counts, 100 μL of BALF cytospin prep-
arations were stained with Diff-Quik reagents (Medion Diagnos-
tics). Two slides with 2 × 100 cells per slide were counted and the 
numbers of neutrophils and AMs were calculated, using the deter-
mined whole cell counts/mL BALF. 
 Assessment of Bacterial Loads and Survival  
 For the survival analysis, mice were monitored for 5 days fol-
lowing infection with  S. pneumoniae  or PBS (uninfected) . Clinical 
conditions, rectal temperature (BAT-12 Microprobe Thermome-
ter; Physitemp Instruments), and body weight were monitored ev-
ery 12 h. Mice were sacrificed when they had lost more than 20% 
of their initial body weight and/or exhibited a decrease in their 
body temperature of  ≥ 4  °  C. For enumeration of bacterial numbers, 
IL-37tg and WT mice were anesthetized at 24 or 48 h after infec-
tion by intraperitoneal injection of ketamine (160 mg/kg) and xy-
lazine (75 mg/kg). Blood samples were taken and mice were final-
ly sacrificed by bleeding via the vena cava. Subsequently, lungs and 
BALF were collected. Lung tissue was homogenized in 500 μL of 
PBS without supplements using a tissue homogenizer (FastPrep-24 
SPS; MP Biomedicals). CFU in lung, BALF, and blood samples 
were determined from serial dilutions plated on 5% sheep blood 
agar plates and incubated for 20 h at 37  °  C/5% CO 2 before colonies 
were counted. The limit of detection was 10 CFU/mL.
 Lung Histopathology and Immunohistochemistry  
 Mice were sacrificed at 24 or 48 h after infection with  S. pneu-
moniae or application of PBS. Lungs were carefully removed after 
ligation of the trachea as described previously  [25] . The lungs were 
immersion-fixed in formalin and embedded in paraffin, cut in 
2-μm-thick sections, and stained with hematoxylin and eosin after 
dewaxing in xylene and rehydration in decreasing ethanol concen-
trations. Three evenly distributed sections per lung were micro-
scopically evaluated by a board-certified veterinary pathologist to 
assess dissemination and the quality of pathologic alterations using 
specified lung inflammation parameters as previously described 
 [26] (total lung area affected; distribution of lung lesions; bronchi-
tis; peribronchial, interstitial, and intra-alveolar inflammation; al-
veolar necrosis; perivascular inflammation and edema; infiltration 
by neutrophils; macrophages; pleuritic; and steatitis). The lung 
histopathological score is expressed as the sum of 5 parameters 
graded on a scale of 0 (absent) to 4 (severe): pleuritis, steatitis, 
pneumonia, perivascular edema, and degree of inflammation. For 
immunohistochemical detection of  S. pneumoniae and active cas-
pase-3, heat-mediated antigen retrieval was performed in 10 m M 
of citric acid (pH 6.0), microwaved at 600 W for 12 min. Thereaf-
ter, lung sections were incubated with a purified rabbit antibody 
polyclonal to  S. pneumoniae (1: 2,000) or with a purified rabbit an-
tibody polyclonal to active caspase-3 (1: 1,000) at 4   °   C overnight. 
Incubation with an immune-purified rabbit antibody at the same 
dilution served as a negative control. Subsequently, slides stained 
for  S. pneumoniae were incubated with a secondary, alkaline phos-
phatase-conjugated goat anti-rabbit (1: 500, AP-1000; Vector, Bur-
lingame, CA, USA) antibody for 30 min at room temperature. The 
alkaline chromogen triamino-tritolyl-methanechloride (Neufuch-
sin) was used as a phosphatase substrate for color development. 
Slides stained for active caspase-3 were incubated with biotinyl-
ated, secondary goat anti-rabbit IgG (1: 200) antibody and HRP-
coupled streptavidin. Diaminobenzidine (DAB) was used as sub-
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strate for color development. All slides were counterstained with 
hematoxylin, dehydrated through graded ethanols, cleared in xy-
lene, and coverslipped.
 ELISA/Bio-Plex 
 Cytokine secretion by murine RAW 264.7  cells was analyzed 
with the commercially available ELISA kits mouse IL-6/IL-1β/
TNF-α ELISA Ready-Set-Go (eBioscience). Levels of cytokines in 
lung homogenates, BALF, and serum were determined by Bio-Plex 
Multiplex Immunoassay (Bio-Rad). Measurement of IL-37 pro-
tein in RAW 264.7 cells, lung homogenates, BALF, and serum was 
carried out with the IL-37 (human) ELISA kit (AdipoGen). All kits 
were used according to the manufacturer‘s protocols.
 RNA Isolation, cDNA Synthesis, and Reverse
Transciption qPCR  
 To quantify the relative gene expression of  IL-37 ,  IL-6 ,  IL-1β , 
and  TNF-α in vitro and in vivo ,  total RNA was extracted and re-
verse transcription qPCR and real-time qPCR were performed as 
previously described  [27] . The  expression levels were normalized 
to the house-keeping gene  Ribosomal Protein L13A ( RPL13A ) . The 
sequences of all primers used for amplification are listed in  Table 1 .
 Phagocytosis and Intracellular Killing Assay 
 RAW-IL-37 and RAW-vector cells were exposed to either
 S. pneumoniae D39 or D39Δ cps with a multiplicity of infection 
(MOI) of 150. Phagocytosis was carried out for 60 min at 37  °  C and 
5% CO 2 . After bacterial exposure, cells were washed and incubated 
for 1 h in culture medium, containing 200 μg/mL of Gentamicin 
(Gibco), which kills extracellular bacteria but does not penetrate 
eukaryotic cells. Then, cells were washed twice in PBS and lysed 
mechanically with a tissue homogenizer (FastPrep-24 SPS; MP 
Biomedicals). The number of ingested bacteria was determined by 
quantitative plating of serial dilutions of the lysates on sheep blood 
agar plates and incubation at 37  °  C and 5% CO 2 for 20 h. The lim-
it of detection was 10 CFU/well. Gentamicin activity was verified 
by plating supernatants after 1 h of incubation with Gentamicin. 
To demonstrate phagocytized bacteria by RAW cells, D39wt and 
D39Δcps were grown to mid-log phase (OD 600 of 0.285) at 37  °  C/5% 
CO 2 and labeled with fluorescein isothiocyanate (FITC; 0.2 mg per 
10 8 bacteria) for 1 h at room temperature and 150 rpmi. Bacteria 
were then washed 4 times with PBS and added to the cells. Phago-
cytosis assay was carried out as described before. After quenching 
of the FITC signal of extracellular adherent bacteria with ethidium 
bromide (1 mg/mL cell suspension; Sigma-Aldrich), confocal 
DIC-fluorescence microscope images of the cells with ingested, 
D39wt, and D39Δcps were taken (ZEISS Axio Vert.1). To monitor 
intracellular killing capacity, cells could phagocytize D39Δcps for 
60 min. Then, cells were washed and Gentamicin (200 μg/mL) was 
added for 1 h. 120, 180, and 240 min after stimulation, cells were 
washed, lysed, and plated as described for the phagocytosis assay. 
The killing efficiency of the internalized bacteria was calculated 
using the following equation: intracellular killing = {[CFU(60 min) 
– CFU(240 min)]/CFU(60min)} ×100%. For studies with recom-
binant IL-37, cells were preincubated with 100 μg/mL recombi-
nant IL-37 for 4 h and then had the same procedure for the killing 
assay as described before. According to the manufacturers, who 
measured its activity by its binding ability in a functional ELISA, 
we used recombinant human IL-37/IL-1F7 protein (R&D). 
 Statistics 
 GraphPad Prism5 software was used to perform statistical anal-
ysis and provide graphical presentation. One-way analysis of vari-
ance (ANOVA) followed by Dunnett’s Multiple Comparison Test 
(Dunn test) was performed to analyze IL-37mRNA and IL-37 pro-
tein levels. Significant differences between treatment groups (WT 
vs. IL-37tg mice; RAW-vector vs. RAW-IL-37) were analyzed with 
the Student  t test. Survival curves were compared by log-rank test. 
In all cases,  p < 0.05 was considered statistically significant.
 Results 
 IL-37 Is Upregulated by S. pneumoniae and Reduces 
Cytokine Expression in Murine RAW Macrophages 
 AMs play a pivotal role in the orchestration of innate 
immune responses by controlling pneumococcal growth 
in the lower airways  [5] . Thereby, AMs and lung epithe-
lial cells release proinflammatory cytokines and chemo-
kines to activate a neutrophilic response. The exaggerated 
neutrophil response worsens the clinical features of pneu-
monia and is associated with severe lung injury  [28] . IL-
37 is upregulated during inflammation and downregu-
lates the inflammatory response of macrophages  [6] . We 
therefore investigated the expression profile and the im-
munomodulatory properties of human IL-37 in murine 
macrophages (RAW 264.7) after stimulation with pneu-
mococci. RAW macrophages, stably transfected with ei-
Table 1.  Human and murine RT-qPCR primers used in this study
Human (h) and mouse (m) gene Symbol Forward primer Reverse primer
h-Interleukin-37 IL-37 GGAAGTCCGATTCTCCTGGGGGT GGCCGGCGTGCTGATTCCTT
m-Interleukin-6 IL-6 ACCACTTCACAAGTCGGAGG TCTGCAAGTGCATCATCGTT
m-Interleukin-1 beta IL-1β AGGAGAACCAAGCAACGACA TCTGCTTGTGAGGTGCTGAT
m-Tumor necrosis factor alpha TNF-α GGCCTCCCTCTCATCAGTTC TTTGCTACGACGTGGGCTAC
m-Ribosomal protein-L13A RPL13A TACGCTGTGAAGGCATCAAC CTCGGGAGGGGTTGGTATTC
m-TNF-related apoptosis-inducing ligand TRAIL GTGGCAGCTCACATTACTGG TAATACAGGCCCTCCTGCTC
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ther pIRES- IL-37b (RAW-IL-37) or pIRES-empty (RAW-
vector; lacking human  IL-37b ), were stimulated with the 
encapsulated  S. pneumoniae strain D39, with the isogen-
ic nonencapsulated deletion mutant strain D39Δ cps , or 
with the TLR2/6 agonist macrophage-activating lipopep-
tide-2 (MALP-2) ( Fig. 1 a, b).
 Each of the  3 stimuli (D39, D39Δ cps , MALP-2) in-
duced a significant increase of IL-37 mRNA. Treatment 
of RAW-IL-37 cells with MALP-2 induced a 16-fold in-
crease in IL-37 mRNA already detectable after 2 h of stim-
ulation. Thereafter, levels of IL-37 mRNA decreased to a 
4-fold expression at 8 h. Exposure to  S. pneumoniae led 
***
*
**
** ** **
**
** **
***
***
***
*
*
*
***
*****
**
***
*
*
****
*
*****
c
d
ba
 Fig. 1. IL-37 is upregulated by  S. pneumoniae and reduces cytokine 
expression in murine RAW macrophages. RAW 264.7 cells, stably 
transfected with either pIRES- IL-37b (RAW-IL-37) or pIRES-
empty (RAW-vector), were stimulated with D39, D39Δ cps (MOI 
0.05), or MALP-2 (0.1 μg/mL) and incubated as indicated.  a IL-37 
mRNA expression level in RAW-IL-37 cells normalized to un-
treated controls analyzed by qPCR after the indicated period of 
stimulation.  b Measurement of IL-37 protein from cell culture su-
pernatants of RAW-IL-37 cells at the indicated time point by ELI-
SA.  c Cytokine mRNA of IL-6, IL-1β, and TNF-α of RAW-vector 
and RAW-IL-37 cells at the indicated time point by qPCR. Values 
are normalized to uninfected controls.  d Detection of cytokine 
protein levels of IL-6, IL-1β, and TNF-α in cell culture superna-
tants of RAW-vector and RAW-IL-37 cells at the indicated time 
point by ELISA. Column bars of  b and  d show means with stan-
dard deviations. Values of  a and  c are represented as means with 
standard errors. Shown are representative data of 3 independent 
experiments ( a–d ).  *    p < 0.05;  * *    p < 0.005;  * * *    p < 0.0005;
 * * * *   p < 0.0001. 
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to a significant 4-fold increase in IL-37 mRNA after 4 h 
and then further increased to 32-fold in response to 
D39Δ cps challenge at 8 h ( Fig. 1 a). However, unless there 
was stimulation, only minor mRNA of IL-37 were detect-
ed (data not shown). In addition, all 3 stimulations led to 
a significant IL-37 protein secretion, detectable by ELISA 
of cell culture supernatants after 24 h of stimulation 
( Fig. 1 b). 
 Next, we analyzed the impact of IL-37 expression and 
secretion on the production of proinflammatory cytokine 
mRNAs and protein levels of IL-6, TNF-α, and IL-1β after 
stimulation with  S. pneumoniae ( Fig.  1 c, d). In RAW-
IL-37 cells, stimulation with D39, D39Δ cps , and MALP-2 
significantly reduced mRNA and protein levels of IL-6, 
TNF-α, and IL-1β compared to RAW vector cells. 
**
a
b c
 Fig. 2. IL-37 expression increases intracellular survival of  S. pneu-
moniae in murine RAW macrophages. RAW 264.7 cells, stably 
transfected with either pIRES- IL-37b (RAW-IL-37) or pIRES-
empty (RAW-vector), were stimulated with D39Δ cps (MOI of 
150).  a Overview of DIC/FITC microscope images of RAW mac-
rophages with ingested, fluorescent FITC-labeled D39Δcps 60 min 
after infection. Twenty-fold magnification. FITC signal of extra-
cellular bacteria was quenched with ethidium bromide. Phagocy-
tosis ( b ) and intracellular ( c ) survival of ingested D39Δ cps . Cells 
could phagocytose bacteria for 60 min. Subsequently, Gentamicin 
(200 μg/mL) was added for 1 h and the number of intracellular 
bacteria was determined by quantitative plating of the cell lysates. 
Data in  a are shown as CFU of recovered bacteria per well. Data in 
 b are expressed as the percentage of surviving bacteria per well 120, 
180, and 240 min after stimulation relative to the number of recov-
ered bacteria after 60 min of stimulation (= 100%). Two wells/
group obtained from 3 independent experiments. Mean values 
with standard errors are shown.  
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 RAW-IL-37 Macrophages Possess Impaired 
Intracellular Killing of S. pneumoniae  
 To investigate whether IL-37 expression has an impact 
on macrophage phagocytic activity during pneumococcal 
stimulation, RAW-IL-37 and RAW-vector cells were ex-
posed to either  S. pneumoniae D39 or D39Δ cps (MOI = 
150). While phagocytosed D39 were rarely seen, or absent 
in both cell lines (online suppl. Fig. S1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000469661), 
the nonencapsulated mutant D39Δ cps was phagocytosed 
by the cells ( Fig. 2 a). Both, RAW-vector and RAW-IL-37 
cells showed similar numbers of ingested D39Δ cps pneu-
* * ****
***
**
**
***
****
a
b
c
 Fig. 3. IL-37tg mice exhibit enhanced bacterial spread and in-
creased mortality upon challenge with  S. pneumoniae . WT and 
IL-37tg mice were inoculated intranasally with  S. pneumoniae D39 
(5 × 10 7 CFU/mouse) or treated with PBS (uninfected).  a Kaplan-
Meier survival plot. Survival rate was assessed over the 96-h period 
following infection.  b Bacterial loads of  S. pneumoniae in lung ho-
mogenates, BALF, and blood at 24 and 48 h after infection. Limit 
of detection was 10 CFU/mL.  c Detection of IL-37 protein in lung 
homogenates, BALF, and serum of IL-37tg mice relative to unin-
fected controls by ELISA. Detection limit: 15 pg/mL. Data in  b are 
given as box and whisker plots showing the smallest observation, 
the lower quartile, the median, the upper quartile, and the largest 
observation. Bars in  c show mean expressions with standard de-
viations.  n = 26 mice ( a );  n = 10 mice ( b );  n = 4 mice ( c ) per group 
and time point of n  ≥ 2 independently performed experiments.
 *   p < 0.05;  * *   p < 0.005;  * * *   p < 0.0005;  * * * *   p < 0.0001 vs. unin-
fected controls ( c ) or WT vs. IL-37tg mice ( a ,  b ). 
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mococci with no differences related to the phagocytosis 
potential ( Fig. 2 b).  
 Next, we analyzed the intracellular killing capacity of 
phagocytosed pneumococci by RAW macrophages. IL-
37-expressing RAW cells demonstrated a 2.2-fold in-
crease of viable bacteria recovered from the cells com-
pared to RAW-vector cells ( Fig. 2 c). Two hundred and 
forty minutes after stimulation with  S. pneumoniae , only 
25% of the ingested bacteria from RAW-vector cells were 
still alive, whereas in RAW-IL-37 cells the survival of in-
tracellular pneumococci was 55% ( Fig. 2 c). In contrast, 
we observed no difference in case of the killing capacities 
when we compared RAW-vector cells, which were prein-
cubated with recombinant IL-37, with RAW-vector cells 
without recombinant IL-37 (online suppl. Fig. S2). Given 
the fact that IL-37 protein accumulates within macro-
phages over a time period of 24 h, at which time IL-37 
protein is not detectable in the supernatant but is detect-
able in the nucleus and the cytosol after stimulation of 
RAW-IL-37 cells with  S. pneumoniae (online suppl. Fig. 
S3), these data indicate that intracellular but not secreted 
IL-37 decreased the ability of RAW macrophages to kill 
intracellular pneumococci.
 IL-37tg Mice Exhibit Enhanced Bacterial Spread and 
Increased Mortality upon Challenge with
S. pneumoniae 
 To investigate the impact of IL-37 in vivo in a pneu-
mococcal pneumonia infection model, WT and IL-37tg 
mice were infected intranasally with D39 or treated with 
the same volume of PBS (uninfected) as control. Infected 
IL-37tg mice showed a significantly increased mortality 
compared to WT mice ( Fig. 3 a). Seventy-two hours after 
infection, 20% of WT mice were still alive, with no further 
mice dying over the next 24 h, while the IL-37tg mice ex-
hibited 100% mortality 72 h after infection ( Fig. 3 a). 
 In accordance with the increased mortality, 24 h after 
infection, IL-37tg mice showed significantly higher bacte-
rial counts in lung homogenates, BALF, and peripheral 
blood compared to WT mice ( Fig. 3 b). Forty-eight hours 
after infection, bacterial loads in IL-37tg mice were still 
significantly higher in lung homogenates and BALF com-
pared to WT mice, while in the peripheral blood, bacterial 
counts reached similar numbers in both groups ( Fig. 3 b).
 Despite a constitutively active cytomegaly (CMV) pro-
motor, transgene expression of IL-37 is low unless there 
is stimulation in mouse and human cell lines as well as in 
IL-37tg mice models  [7, 29–31] . To determine whether 
infection with  S. pneumoniae induces the expression of 
the IL-37 transgene, we assessed the in vivo kinetics of IL-
37 by analyzing IL-37 mRNA in lung homogenates (on-
line suppl. Fig. S4) as well as protein levels in the lung, 
BALF, and serum of infected IL-37tg mice ( Fig. 3 c). Al-
though baseline expression was minimal (data not 
shown), IL-37 mRNA levels were increased at 8 h after 
infection, followed by a secondary increase at 24 h after 
infection (online suppl. Fig. S4). Thereafter, 48 h after in-
fection, the levels decreased. In addition, we observed in 
IL-37tg mice that IL-37 protein levels in lung homoge-
nates and BALF increased significantly relative to unin-
fected controls 24 and 48 h after infection ( Fig. 3 c). In 
contrast, we found only marginal amounts IL-37 protein 
in the serum of infected IL-37tg mice, detectable only
48 h after infection ( Fig. 3 c). These data indicate that pul-
monary  S. pneumoniae infection, which resulted in an en-
hanced early spread of the pathogen and increased mor-
tality, was required for the induction of IL-37.
 Transgene Expression of IL-37 in the Lung Exerts 
Biphasic Effects on Cytokine Production after 
Pneumococcal Infection 
 Based on the increased systemic spread of  S. pneu-
moniae in infected IL-37tg mice, we hypothesized that 
IL-37tg mice would exhibit hyperinflammatory respons-
es after pneumococcal infection. Therefore, we analyzed 
the mRNA levels of the proinflammatory cytokines IL-6 , 
 IL-1β, and TNF-α in the lungs of infected animals at 8, 24, 
and 48 h after infection ( Fig. 4 a). At 8 h after infection, we 
observed significantly lower mRNA levels of IL-6 ,  IL-1β, 
and TNF-α in the lungs of IL-37tg mice compared to 
lungs of WT mice ( Fig. 4 a). This initial lower expression 
was followed by a significant increase and higher expres-
 Fig. 4. Transgene  expression of IL-37 in the lung exerts biphasic 
effects on cytokine production after pneumococcal infection. WT 
and IL-37tg mice were challenged intranasally with  S. pneumoniae 
D39 (5 × 10 7 CFU/mouse) or treated with PBS (uninfected). Lungs 
and peripheral blood were collected at the indicated time points 
for analysis of: mRNA expression of IL-6, IL-1β and TNF-α in lung 
homogenates normalized to uninfected controls by qPCR ( a ), and 
cytokine protein levels of IL-6, TNF-α, IL-1β, KC, IFN-γ, MCP-1, 
G-CSF, M-CSF, and IL-10 in lung homogenates and serum by Bio-
Plex ( b ,  c ). Values of  a are represented as means ± SEM. Column 
bars of  b and  c show means with standard errors.  n  ≥ 6 mice ( a ),
 n = 4 mice ( b ) per group and time point of n  ≥ 2 independently 
performed experiments.  *    p < 0.05;  * *    p < 0.005;  * * *    p < 0.0005; 
 * * * *   p < 0.0001 WT vs. IL-37tg mice. 
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sion of IL-6 ,  IL-1β, and TNF-α mRNA in the lungs of IL-
37tg mice compared to WT mice, beginning at 24 h after 
infection ( Fig. 4 a). In addition, we measured a panel of 
cytokines and chemokines during pneumococcal infec-
tion at the indicated time points ( Fig. 4 b, c; online suppl. 
Fig. S5). In accordance with the mRNA levels, we could 
observe significant lower levels of IL-6 and G-CSF pro-
tein 8 h after infection in the lungs of IL-37tg mice com-
pared to WT mice, while the other measured cytokines 
showed similar protein contents in the lungs of both 
groups. During the course of infection, most cytokines 
were markedly higher in IL-37tg mice, particularly 48 h 
after infection, including IL-6, TNF-α, KC, IFN-γ, G-
CSF, M-CSF, and IL-10 in the lungs ( Fig. 4 b); IL-6, TNF-α, 
IL-1β, KC, IFN-γ, MCP-1 (CCL2), and IL-10 in the serum 
( Fig. 4 c); and MCP-1 (CCL2), G-CSF and IL-10 in BALF 
(online suppl. Fig. S5). These data indicate that IL-37 crit-
ically modulates the inflammatory responses during the 
early phase of pneumococcal pneumonia by reducing the 
amounts of proinflammatory cytokines. This early phase 
with reduced proinflammatory cytokine expression is fol-
lowed by a second phase of exaggerated cytokine and che-
mokine release as a response to the systemic spread of  S. 
pneumoniae in IL-37tg mice compared to WT animals.
 Infected IL-37tg Mice Show Increased Alveolar 
Macrophage and Neutrophil Recruitment and 
Decreased Pulmonary TRAIL Expression 
 KC and CCL2 play a key role in regulating leukocyte 
migration into inflamed murine lung tissue  [32, 33] . To 
investigate whether the observed differences in mortality 
between WT and IL-37tg mice are associated with differ-
ences in leukocyte recruitment into the infected lungs, we 
examined alveolar leukocyte numbers in WT and IL-37tg 
mice infected with  S. pneumoniae via Diff-Quik staining 
( Fig. 5 a, b; online suppl. Fig. S6). Notably, 48 h after infec-
tion we observed 2-fold higher counts of AMs in the 
BALF of IL-37tg mice relative to WT mice ( Fig. 5 a). We 
also observed a doubling of the number of neutrophils in 
the BALF of IL-37tg mice relative to WT mice 48 h after 
infection ( Fig. 5 b). Neutrophils have been identified to be 
the primary source of TRAIL expression in the lungs of
 S. pneumoniae -infected mice. Increased levels of TRAIL 
have been shown to induce AM apoptosis, which reduces 
inflammation during pneumococcal pneumonia  [5] . To 
investigate whether IL-37 expression modulates the ex-
pression of TRAIL, we examined TRAIL  mRNA levels in 
the lungs of IL-37tg mice and in WT mice ( Fig. 5 c). Forty-
eight hours after infection, we observed a significant 
3-fold reduction of TRAIL mRNA expression in the lungs 
**
*
**
a
b
c
 Fig. 5. Infected IL-37tg mice show increased alveolar macrophage 
and neutrophil recruitment and decreased pulmonary TRAIL ex-
pression. WT and IL-37tg mice were inoculated intranasally with
 S. pneumoniae D39 (5 × 10 7 CFU/mouse) or treated with PBS (unin-
fected).  a Alveolar macrophage numbers in BALF 24 and 48 h after 
infection.  b Neutrophil numbers in BALF 24 and 48 h after infection. 
 c  Analysis of  mRNA expression of TRAIL  in lung homogenates 24 
and 48 h after infection normalized to uninfected controls by qPCR. 
Column bars are represented as means with standard errors.  n  ≥ 4 ( a , 
 b );  n  ≥ 5 ( c ) mice per group and time point of  n  ≥ 2 independently 
performed experiments.  *   p < 0.05;  * *   p < 0.005 WT vs. IL-37tg mice. 
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of IL-37tg mice compared to WT mice ( Fig. 5 c). Overall, 
these data support the important role of the  S. pneumoni-
ae -induced IL-37 expression for impeding pathogen 
clearance and deteriorating immunopathology. 
 Transgene IL-37 Expression Results in Augmented 
Death of Neutrophils, Increased Tissue Damage, 
and Pneumococcal Overgrowth after Pneumococcal 
Infection 
 Excessive infiltration of neutrophils in the lungs has 
been demonstrated to result in augmented tissue destruc-
tion  [34, 35] . To elucidate the effect of the IL-37-mediated 
massive influx of neutrophils into alveolar spaces and re-
duced TRAIL expression levels on pulmonary tissue dam-
age, lungs of  S. pneumoniae -infected IL-37tg and WT mice 
were dissected 48 h after infection and 2-μm sections were 
prepared and stained with hematoxylin and eosin or with 
an anti-active caspase-3 antibody or anti- S. pneumoniae 
antibody for histopathological and immunohistochemical 
analyses ( Fig. 6 a–d). Pneumococcal infection resulted in 
severe suppurative pleuropneumonia in both groups. WT 
mice had prominent infiltration of numerous intact neu-
trophils into the lung parenchyma and perivascular areas, 
consistent with predominantly suppurative pneumonia, 
without much necrosis of the lung parenchyma ( Fig. 6 a, b, 
left panels). In contrast, IL-37tg mice had excessive multi-
focal to confluent parenchymal necrosis, accompanied by 
massive neutrophil cell death, as indicated by neutrophil 
fragmentation, decay, loss of cellular details, accumulation 
of cellular and karrhyorectic debris, and karyorhexis, 
karyopyknosis, and karyolysis ( Fig.  6 a, b, right panels). 
Furthermore, active caspase-3 immunostaining as a mark-
er for apoptotic cell death labeled only a few randomly scat-
tered cells in the inflamed lung parenchyma without dif-
ferences between the WT and IL-37tg mice (online suppl. 
Fig. S7, arrowheads). Specifically, areas of tissue necrosis 
in the IL-37tg mice were devoid of active caspase-3 immu-
nolabeling (online suppl. Fig. S7, asterisks), ruling out the 
involvement of apoptosis. Importantly, in IL-37tg mice, a 
large number of pneumococci were present predominant-
ly in perivascular spaces, which were far fewer in number 
in WT mice ( Fig. 6 c, arrowhead, stained in red). Using a 
lung histopathology score assessing the percentage of af-
fected lung area, significantly more widespread lung in-
flammation was observed in the IL-37tg mice relative to 
WT mice 48 h after infection ( Fig. 6 d). These data suggest 
that the increased mortality of IL-37tg mice was due to im-
paired bacterial killing with overgrowth and spread of 
pneumococci, massive necrosis of lung parenchyma, and 
marked death of neutrophils.
 Discussion 
 In this study, we investigated the functional role of IL-
37 in host defense against  S. pneumoniae . Here, we show 
that IL-37, expressed in lung tissue during infection, in-
creases bacterial spread and disease pathology of pneu-
mococcal pneumonia. Our in vitro results are in agree-
ment with recent findings describing IL-37 as an inhibitor 
of the innate immune system by suppressing important 
proinflammatory cytokines after TLR stimulation of mu-
rine macrophages  [7] . We observed that the stimulation 
of RAW macrophages with  S. pneumoniae reduced
the production of the proinflammatory cytokines IL-6, 
TNF-α, and IL-1β in RAW-IL-37 cells compared to 
RAW-vector cells. Importantly, expression of IL-37 led to 
an enhanced intracellular survival of  S. pneumoniae . We 
further showed in a murine infection model that mice, 
expressing IL-37, exhibited significantly increased mor-
tality compared to WT mice upon infection with  S. pneu-
moniae . During the early phase of infection, IL-37tg mice 
revealed limited proinflammatory cytokine responses 
during pneumococcal infection which was followed by an 
excessive increase in bacterial burden and increased ex-
pression of cytokines and chemokines in the lungs at lat-
er time points of infection. In parallel, we observed an 
enhanced alveolar recruitment of AMs and neutrophils, 
while TRAIL expression was significantly decreased in 
the lungs of the infected IL-37tg mice. This resulted in 
both increased neutrophil influx and massive coloniza-
tion of pneumococci in the lungs leading to prominent 
necrotizing lung tissue damage and increased mortality. 
 As a fundamental suppressor of innate immune func-
tions, IL-37 has been shown to be expressed by human 
blood monocytes, tissue macrophages, and other im-
mune cells in response to the TLR2 and TLR4 agonists 
MALP-2 and LPS  [6] . Due to the lack of a homologous 
IL-37 murine gene, our studies were based on vector-con-
trolled human IL-37 murine expression models where IL-
37 expression is regulated by a constitutive CMV pro-
moter  [7] . However, like other members of the IL-1 fam-
ily, IL-37 shows no species specificity, and transgene 
expression of human IL-37 in RAW macrophages as well 
as in mice is similar to the expression in human cells  [21] . 
In our study, we show that unless there is stimulation, 
only minor IL-37 levels were detected in RAW-37 mac-
rophages as well as in IL-37tg mice. However, upon expo-
sure with  S. pneumoniae ,  IL-37 expression and secretion 
progressively increased in vitro and in vivo. The abun-
dance of IL-37 transcripts is low under steady-state con-
ditions in dendritic cells and human blood monocytes. 
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This is due to an instability sequence in the IL-37b-coding 
region which induces constitutive downregulation of IL-
37b mRNA in transfected cells unless stimulated, and in-
dicates that mRNA stabilization is the relevant mecha-
nism to regulate IL-37 expression in IL-37-transfected 
murine as well as in human macrophages  [31] . In addi-
tion, constitutive expression of human IL-37 was low in 
in vivo models of spinal cord injury and DSS-induced 
colitis  [29, 30] . In parallel, our data suggest that inflam-
matory conditions, caused by  S. pneumoniae , increase the 
half-life of IL-37 mRNA and allows for translation of the 
IL-37 protein. The observed discrepancy between the 
mRNA expression levels and the corresponding protein 
contents of IL-6, TNF-α, and IL-1β could be explained by 
the fact that mRNAs are produced at a much lower rate 
than proteins in mammalian cells. While a mammalian 
cell produces 2 copies of a given mRNA per hour, dozens 
of copies of the corresponding protein per mRNA per 
hour is produced. Similarly, mRNAs are less stable than 
proteins, with an average half-life of 2.6–7 versus 46 h, 
respectively  [36, 37] . The long half-lives of proteins have 
been confirmed by independent studies in other systems 
 [38, 39] . Therefore, the mRNA level of a gene does not 
usually predict its protein level.
 The elimination of bacteria from the lungs and the pre-
vention of systemic dissemination is the key objective in 
host defense in pneumococcal pneumonia. This is initi-
ated by detection and phagocytosis of  S. pneumoniae by 
innate immune cells and the secretion of cytokines and 
chemokines to coordinate the second-line immune de-
fense  [40] . Thereby, AMs are important early effectors of 
innate immune responses against  S. pneumoniae . These 
specialized cells are efficient in the killing of internalized 
pneumococci. However, this process is known to become 
overwhelmed when bacterial numbers increase  [41] . Im-
portantly, we observed that IL-37 expression in RAW 
macrophages decreased the capacity of these cells to kill 
pneumococci intracellularly. In contrast, we saw no dif-
ference in the killing capacity when we added recombi-
nant IL-37 to RAW-vector cells and compared it to RAW-
vector cells without preincubation with recombinant IL-
37. Previous studies showed that IL-37 is present in the 
cytoplasm and in the nucleus, and thus acts intracellu-
larly after LPS stimulation of stably transfected RAW 
macrophages  [21] . We also could detect IL-37 protein in 
the nucleus and the cytoplasm, but not in the supernatant 
within 24 h of stimulation with  S. pneumoniae . This sug-
gests that the observed impaired killing capacity of pneu-
mococci by RAW macrophages is likely not an effect of 
secreted but of intracellular IL-37.
 In parallel, our findings of increased pneumococcal 
burden in IL-37tg mice at later stages of the disease sug-
gest that the IL-37-mediated decrease in the killing capac-
ity of pneumococci by RAW macrophages might be re-
lated to an early failure of this first-line pulmonary de-
fense for the clearance of pneumococci. Moreover, our 
data suggest that the increase in pneumococcal burden in 
IL-37tg mice may activate AMs in a larger area of the in-
fected lung, resulting in subsequent elevated cytokine and 
chemokine production  [42] . This is demonstrated by the 
fact that after the initial phase, when IL-37 expression re-
duces the proinflammatory response in the infected lungs 
on the mRNA and protein level, an increased expression 
of cytokines and chemokines was detected at later time 
points. Therefore, the initially reduced secretion of cyto-
kines and chemokines and the reduction of intracellular 
killing capacity of macrophages, mediated by IL-37, re-
sults in increased numbers of infiltrating neutrophils at a 
later time point, enabling increased survival and spread-
ing of  S. pneumoniae in the infected lungs of IL-37tg mice. 
Uncontrolled spreading of the bacteria leads to a larger 
area of inflamed lung tissue that result in a secondary 
phase of the disease, characterized by a massive release of 
cytokines and chemokines in the inflamed lung tissue. 
This is followed by increasing numbers of infiltrating leu-
kocytes and massive tissue damage, evoked by activated 
macrophages due to lower expression levels of TRAIL in 
the infected lungs of IL-37tg mice. 
 Pneumococcal pneumonia is characterized by an in-
tense inflammatory response, orchestrated mainly by cy-
 Fig. 6. Transgene IL-37 expression results in augmented death of 
neutrophils, increased tissue damage, and pneumococcal over-
growth after pneumococcal infection. WT and IL-37tg mice were 
inoculated intranasally with  S. pneumoniae D39 (5 × 10 7 CFU/
mouse).  a–c Lung histology 48 h after infection. 2-μm lung sec-
tions were stained with hematoxylin and eosin ( a ,  b ) or with an 
anti- S. pneumoniae antibody ( c ) for histopathological and immu-
nohistochemical analysis. Representative images are shown.
 d Lung histopathological score, expressed as the sum of 5 param-
eters graded on a scale of 0 (absent) to 4 (severe): pleuritis, steatitis, 
pneumonia, perivascular edema, and degree of inflammation. 
Data were assessed 24 or 48 h after infection. Values of  d are rep-
resented as means with standard deviations.  n = 6 (a–d) mice per 
group of n  ≥ 2 independently performed experiments.  *   p < 0.05; 
 * *   p < 0.005 WT vs. IL-37tg mice. Bar ( a–c ) = 20 μm. 
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tokines. Thereby, the infection is a dynamic process 
where time has taken an important role referring to bac-
terial growth  [43, 44] . Our data suggest that the early sup-
pression of proinflammatory cytokines by IL-37 in the 
initial phase during infection with  S. pneumoniae is cru-
cial in determining whether the infection might be con-
trolled or progresses to bacteremic disease. Therefore, 
each cytokine, upregulated in response to the IL-37-in-
duced modulation of the immune response, might be spe-
cifically involved in exacerbating disease pathology. The 
downregulation of IL-1β, which has been shown to be 
required for protective immunity against respiratory in-
fections with  S. pneumoniae , may aggravate the pathogen 
ability to invade sterile compartments where it can con-
tinue multiplication without being eliminated  [45, 46] . 
Moreover, the elevated levels of IL-1β, which we observed 
later in infected IL-37tg mice, have the potential to aggra-
vate tissue damage  [13] . In the early phase of infection, 
we also detected decreased TNF-α levels in the IL-37tg 
mice compared to the WT mice. Our data therefore con-
firm the findings of previous studies in which the secre-
tion of TNF-α has also been found to be of importance for 
the host response to protect from the enhanced pneumo-
coccal spread  [47, 48] . 
 It is also worth mentioning the significantly higher lev-
els of the anti-inflammatory cytokine IL-10, detected in 
lung, BALF, and blood of IL-37tg mice. IL-10 has been 
shown to impair host defense in murine pneumococcal 
pneumonia, leading to an unimpeded spread of bacteria 
and increased mortality  [49] . Furthermore, a mouse in-
fection model with  A. fumigatus showed increased IL-10 
levels in lung tissue after treatment of WT mice with re-
combinant IL-37  [13] . Therefore, elevated IL-10 protein 
levels in the IL-37tg mice likely further intensifies the im-
munosuppressive effect of IL-37. Moreover, the fact that 
IL-10 enhanced the bacterial growth in human mononu-
clear phagocytes suggests that the increased IL-10 levels 
in IL-37tg mice might contribute to impairing the intra-
cellular killing of  S. pneumoniae in macrophages  [50] . 
 Neutrophils have been shown to be of critical impor-
tance for the control of pneumococcal infection  [44] . Our 
data showed an up to 50% increase in the levels of the 
neutrophil chemoattractant (KC) and MCP-1 (CCL2) in 
the BALF and peripheral blood of the infected IL-37tg 
mice 24 and 48 h after infection. These cytokines induce 
activation, migration, and infiltration of macrophages 
and neutrophils into the lungs and activate neutrophils 
for increasing respiratory burst activity  [44, 51] . Howev-
er, prolonged attraction of neutrophils, caused by en-
hanced levels of pulmonary chemokines, is a known risk 
factor for the development of acute lung injury through 
the release of oxidants and proteinases  [52] . The over-
whelming presence of neutrophils in the lungs of the IL-
37tg mice are likely due to the increased KC and MCP-1 
levels, thus triggering the massive inflammation in the 
surrounding lung tissue. This led to necrotizing pneumo-
nia accompanied by disruption of the alveolar barrier and 
pulmonary edema. Furthermore, the uncontrolled 
growth of the pneumococci in the lungs of the IL-37tg 
mice despite a strong macrophage and neutrophil re-
cruitment highlights the fact that the lungs must be 
cleared from the bacteria before their growth surpasses a 
threshold where even a strong inflammatory response 
will not be able to contain the infection.
 An important feature of  S. pneumoniae -induced lung 
infection is the TRAIL-induced apoptosis of AMs, which 
favors pneumococcal elimination and, additionally, lim-
its overwhelming lung inflammation in response to infec-
tion  [5] . At sites of inflammation, TRAIL has also been 
shown to induce apoptosis of neutrophils, which are then 
phagocytized by macrophages favoring the resolution of 
inflammation  [53, 54] . Remarkably, in the lungs of IL-
37tg mice, we observed significant lower levels of TRAIL 
mRNA at 48 h after infection, despite increased alveolar 
recruitment of AMs and neutrophils, demonstrating that 
the initiation of the resolution phase of infection is af-
fected by IL-37 expression. We further observed marked 
death and decay of neutrophils in the lungs of infected 
IL-37tg mice. Neutrophils were most likely recruited by 
the increased expression of chemokines and subsequent-
ly failed to undergo controlled cell death because of re-
duced TRAIL expression  [54] . This cascade likely con-
tributed to increased tissue damage and pneumococcal 
spread as well as the development of necrotizing pneu-
monia and increased mortality  [5, 55] . 
 Overall, it appears reasonable to assume that the inter-
action of pro- and anti-inflammatory immune responses 
during pneumococcal pneumonia must be tightly regu-
lated to achieve a balance between effective pathogen 
elimination and limited damage to the lung parenchyma, 
to prevent a lethal outcome. Our data show that the pow-
erful anti-inflammatory properties of IL-37 substantially 
impair the capability of mice to control pulmonary pneu-
mococcal infection. IL-37 substantially modulates several 
core components of the initial host response to bacterial 
inoculation, thus permitting subsequent bacterial prolif-
eration, recruitment of phagocytes into the lungs, and 
paradoxically increased pulmonary and systemic inflam-
mation. This suggests that an initial intervention in the 
host defense against  S. pneumoniae by suppressing pro-
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inflammatory cytokines through IL-37 is detrimental, 
causing an inflammatory event that and can no longer be 
controlled by the immune system during infection, lead-
ing to higher mortality rates. In conclusion, these data 
shed light on a potential unintended adverse effect that 
therapeutic approaches aiming to augment IL-37 func-
tion should be mindful of. 
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